<DOC>
	<DOCNO>NCT01737151</DOCNO>
	<brief_summary>This clinical trial study stereotactic body radiation therapy treat patient low- intermediate-risk prostate cancer . Stereotactic body radiation therapy may able send x-ray directly tumor cause less damage normal tissue .</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy Treating Patients With Low- Intermediate-Risk Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate , term late toxicity , safety stereotactic radiation therapy use propose fractionation schedule . SECONDARY OBJECTIVES : I . To evaluate , term acute toxicity , safety stereotactic radiation therapy use propose fractionation schedule . II . To determine stereotactic treatment efficacy biochemical failure ( Phoenix criterion ) . III . To determine protocol completion rate . IV . To describe patient-reported outcome use International Index Erectile Function ( IIEF ) EPIC Urinary Bowel Assessment questionnaires . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients undergo standard daily fraction stereotactic body radiation therapy ( SBRT ) 7-8.5 week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Patients must low intermediate risk adenocarcinoma prostate define : Lowrisk disease Histopathology score ( Gleason sum ) : = &lt; 6 , Tstage ( per current AJCC staging criterion ) : T1cT2a , PSA : &lt; 10 Intermediaterisk disease either : Histopathology score ( Gleason sum ) = &lt; 6 , Tstage ( per current American Joint Committee Cancer [ AJCC ] stag criterion ) : T1cT2a , prostatespecific antigen ( PSA ) &gt; 10 = &lt; 20 ; Histopathology score ( Gleason sum ) 7 = &lt; 50 % core positive , Tstage ( per current AJCC staging criterion ) : T1cT2a , PSA &lt; 10 Charlson index comorbidity score = &lt; 4 Ability understand willingness sign write informed consent document Patients history inflammatory bowel disease , require steroid cytotoxic therapy collagen vascular disease Patients history cancer skin cancer within 5 year initiation protocol treatment Patients history pelvic irradiation reason Life expectancy &lt; 10 year Prior treatment antiandrogen , luteinizing hormonereleasing hormone ( LHRH ) agonist , combination two Prior radiation therapy , brachytherapy , cryotherapy Prior surgical procedure involve perirectal periprostatic area</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>